BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/5/2022 1:22:29 AM | Browse: 284 | Download: 513
Publication Name World Journal of Clinical Cases
Manuscript ID 74783
Country Croatia
Received
2022-01-06 16:00
Peer-Review Started
2022-01-06 16:01
To Make the First Decision
Return for Revision
2022-03-10 22:23
Revised
2022-04-10 19:48
Second Decision
2022-05-10 02:52
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief
2022-05-14 07:29
Articles in Press
2022-05-14 07:29
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2022-06-17 01:58
Publish the Manuscript Online
2022-07-05 01:22
ISSN 2307-8960 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Opinion Review
Article Title Semaglutide might be a key for breaking the vicious cycle of metabolically associated fatty liver disease spectrum?
Manuscript Source Invited Manuscript
All Author List Maja Cigrovski Berkovic, Tanja Rezic, Ines Bilic-Curcic and Anna Mrzljak
ORCID
Author(s) ORCID Number
Maja Cigrovski Berkovic http://orcid.org/0000-0003-0750-9785
Tanja Rezic http://orcid.org/0000-0001-8205-8924
Ines Bilic-Curcic http://orcid.org/0000-0002-8861-5987
Anna Mrzljak http://orcid.org/0000-0001-6270-2305
Funding Agency and Grant Number
Corresponding Author Anna Mrzljak, PhD, Adjunct Associate Professor, Department of Gastroenterology and Hepatology, University Hospital Centre Zagreb, Kispaticeva ul 12, Zagreb 10000, Croatia. anna.mrzljak@gmail.com
Key Words Semaglutide; Non-alcoholic fatty liver disease; Glucagon-like peptide-1 receptor agonists; Metabolically associated fatty liver disease
Core Tip The pathogenesis of metabolically associated fatty liver disease (MAFLD) is closely interrelated to type 2 diabetes mellitus (T2DM), with insulin resistance and hyperinsulinemia as key characteristics. Glucagon-like peptide-1 receptor agonists have a favorable effect on glycemic management and weight loss in T2DM patients. Semaglutide is an especially interesting agent with favorable metabolic actions in patients sharing T2DM and MAFLD (but also sole MAFLD) phenotype, available in injectable and oral formulation, thus more attractive for a broader spectrum of patients.
Publish Date 2022-07-05 01:22
Citation Cigrovski Berkovic M, Rezic T, Bilic-Curcic I, Mrzljak A. Semaglutide might be a key for breaking the vicious cycle of metabolically associated fatty liver disease spectrum? World J Clin Cases 2022; 10(20): 6759-6768
URL https://www.wjgnet.com/2307-8960/full/v10/i20/6759.htm
DOI https://dx.doi.org/10.12998/wjcc.v10.i20.6759
Full Article (PDF) WJCC-10-6759.pdf
Full Article (Word) WJCC-10-6759.docx
Manuscript File 74783_Auto_Edited-LS.docx
Answering Reviewers 74783-Answering reviewers.pdf
Audio Core Tip 74783-Audio core tip.m4a
Conflict-of-Interest Disclosure Form 74783-Conflict-of-interest statement.pdf
Copyright License Agreement 74783-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate 74783-Language certificate.pdf
Peer-review Report 74783-Peer-review(s).pdf
Scientific Misconduct Check 74783-CrossCheck.png
Scientific Misconduct Check 74783-Bing-Gong ZM-2.png
Scientific Editor Work List 74783-Scientific editor work list.pdf
CrossCheck Report 74783-CrossCheck report.pdf